2391. Establishing the Optimal Viral Load Threshold for Initiation of Therapy for Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients: A Prospective Derivation Cohort Study Using the International Standardized CMV Quantitative Nucleic Acid Testing
Session: Poster Abstract Session: Transplantation - Prophylaxis and Prediction
Saturday, October 7, 2017
Room: Poster Hall CD

Background: Cytomegalovirus infection remains a critical concern following hematopoietic stem cell transplantation (HSCT). Despite the international standardization in CMV viral load (VL) monitoring, establishment of a threshold viral load to guide preemptive management has yet to be determined. Our primary goal is to obtain a threshold CMV VL for the early detection of clinically significant viremia and, subsequently, for guiding initiation of early management. Secondary goals are to provide clarification to diagnosing clinically significant CMV viremia and to develop an algorithm to ease clinical decision-making.

Methods: A prospective cohort analysis of CMV viral loads using the COBAS¨ AmpliPrep/COBAS¨ TaqMan¨ CMV Test (CAP/CTM) was conducted in all HSCT recipients undergoing weekly CMV monitoring at Henry Ford Hospital, Detroit, MI from April 2015 to December 2016. Plasma CMV Quantitative PCR analysis was performed using the CAP/CTM assay. CMV VL were then calibrated to the WHO international standard and reported in international units (IU/ml of plasma). Each event of early CMV viremia was then categorized as clinically significant or non-clinically significant. A ROC curve analysis was then utilized to identify the optimal CMV VL threshold value for predicting clinically significant CMV viremia.

Results: 63 allogeneic HSCT recipients were included in the study with a total of 240 (viremic and non-viremic) events observed. 22 patients experienced a total of 27 CMV viremic events. 26/27 CMV events were clinically significant. Using a ROC curve, a viral load of 329 IU/ml of plasma was determined as the optimal threshold value for predicting clinically significant CMV viremia (sensitivity 100%, specificity 99.5%, NPV 100%, PPV 96.3%).

Conclusion: Our study offers a novel approach to classifying and detecting early clinically significant CMV viremia and a preliminary threshold CMV VL value at which preemptive therapy should be considered. A prospective validation cohort is currently in progress.


Zachary Hanna, (DO)1, Megan Karrick, (DO)2, Rachna Jayaprakash, MD2, William Morgan, (DO)2, Samaa Lutfi, (DO)2, Kulothungan Gunasekaran, MD2, Ramon Del Busto, MD2, George Alangaden, MD, FIDSA2, Odaliz Abreu-Lanfranco, MD2, Linoj Samuel, PhD., D(ABMM)3 and Mayur Ramesh, MD2, (1)Infectious Diseases, Michigan State University College of Osteopathic Medicine, Detroit, MI, (2)Infectious Diseases, Henry Ford Health System, Detroit, MI, (3)Microbiology, Henry Ford Hospital, Detroit, MI


Z. Hanna, None

M. Karrick, None

R. Jayaprakash, None

W. Morgan, None

S. Lutfi, None

K. Gunasekaran, None

R. Del Busto, None

G. Alangaden, None

O. Abreu-Lanfranco, None

L. Samuel, None

M. Ramesh, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.